14 results on '"Rueda, Johana"'
Search Results
2. Adverse treatment outcomes in multidrug resistant tuberculosis go beyond the microbe-drug interaction: Results of a multiple correspondence analysis.
- Author
-
Tobón, Ángela, Rueda, Johana, Cáceres , Diego H., Mejía, Gloria I., Zapata, Elsa M., Montes, Fernando, Ospina, Antonio, Fadul, Santiago, Paniagua, Lizeth, Robledo, Jaime, Tobón, Ángela, Rueda, Johana, Cáceres , Diego H., Mejía, Gloria I., Zapata, Elsa M., Montes, Fernando, Ospina, Antonio, Fadul, Santiago, Paniagua, Lizeth, and Robledo, Jaime more...
- Abstract
Introduction: Multidrug-resistant tuberculosis treatment is effective in 50% of patients due to several factors including antibiotic susceptibility of the microorganism, adverse treatment reactions, social factors, and associated comorbidities.Objectives: In this study, we describe the demographics, clinical characteristics, and factors associated with treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) patients in Medellín, Colombia.Materials and methods: We conducted a retrospective analysis using data from patients diagnosed with MDR-TB attending Hospital La María in Medellín, Colombia, for treatment between 2010 and 2015. Patients were categorized as having successful (cured) or poor (failure, lost to follow-up, and death) treatment outcomes. Associations between demographic, clinical factors, laboratory results, treatment outcomes, and follow-up information were evaluated by univariate, multivariate, and multiple correspondence analyses.Results: Of the 128 patients with MDR-TB, 77 (60%) had successful outcomes. Of those with poor outcomes, 26 were lost to follow-up, 15 died, and 10 were treatment failures. Irregular treatment, the presence of comorbidities, and positive cultures after more than two months of treatment were associated with poor outcomes compared to successful ones (p<0.05 for all). The multiple correspondence analyses grouped patients who were lost to follow-up, had HIV, and drug addiction, as well as patients with treatment failure, irregular treatment, and chronic obstructive pulmonary disease.Conclusion: The recognition of factors affecting treatment is essential and was associated with treatment outcomes in this series of patients. Early identification of these factors should increase the rates of treatment success and contribute to MDR-TB control., Introducción. El tratamiento de la tuberculosis multirresistente tiene una efectividad del 50 %, afectado por múltiples factores como la sensibilidad del microorganismo, las reacciones secundarias, los factores sociales y las comorbilidades existentes.Objetivos. Describir la demografía, las características clínicas y los factores pronósticos asociados con los resultados del tratamiento en pacientes multirresistentes (TB-MDR) de Medellín, Colombia.Métodos. Se hizo un análisis retrospectivo de los datos de los pacientes con TB-MDR atendidos en el Hospital La María de Medellín, Colombia, que fueron tratados entre el 2010 y el 2015. Los pacientes se categorizaron con tratamiento exitoso (curados) o con tratamiento fallido (falla en el tratamiento, pérdida durante el seguimiento y muerte). Se determinó la asociación entre las características demográficas y clínicas, los resultados de los exámenes de laboratorio, los desenlaces del tratamiento y la información del seguimiento, utilizando análisis univariado, multivariado y de correspondencia múltiple.Resultados. De 128 pacientes con TB-MDR, 77 (60 %) tuvieron un tratamiento exitoso. De los que tuvieron un tratamiento fallido, 26 pacientes se perdieron en el seguimiento, 15 murieron y 10 tuvieron falla en el tratamiento. El tratamiento irregular, las comorbilidades y los cultivos positivos más allá de 2 meses de tratamiento se asociaron significativamente con los tratamientos fallidos (p<0,05). El análisis de correspondencia múltiple agrupó los pacientes con pérdida en el seguimiento, con HIV y tratamientos irregulares, y los pacientes con tratamientos irregulares y enfermedad pulmonar obstructiva crónica con falla en el tratamiento y muerte.Conclusión. El reconocimiento temprano de los factores que afectan el desenlace del tratamiento de los pacientes con TB-MDR es esencial; la identificación de dichos factores debería incrementar el éxito del tratamiento y contribuir al adecuado control de la TB-MDR. more...
- Published
- 2020
Catalog
3. Tuberculosis in farm workers exposed to dairy and beef livestock in Colombia
- Author
-
Muñoz, Catalina, primary, Rueda, Johana, additional, Botero, Luz E., additional, Mejía, Gloria I., additional, Cardona, Ximena, additional, Jaramillo, Manuel G., additional, and Robledo, Jaime, additional more...
- Published
- 2019
- Full Text
- View/download PDF
4. Efectos del implante intravítreo de dexametasona (Ozurdex) en la presión intraocular para el tratamiento del edema macular
- Author
-
Arrascue, Sergio, primary, Rueda, Johana, additional, Unigarro, Juan, additional, Vidal, Sofía, additional, Espinosa, Linda, additional, Abdala-Caballero, Carlos, additional, and Acosta-Reyes, Jorge, additional more...
- Published
- 2019
- Full Text
- View/download PDF
5. Effects of the dexamethasone intravitreal implant (Ozurdex) on intraocular pressure for the treatment of macular edema
- Author
-
Arrascue, Sergio, primary, Rueda, Johana, additional, Unigarro, Juan, additional, Vidal, Sofía, additional, Espinosa, Linda, additional, Abdala-Caballero, Carlos, additional, and Acosta-Reyes, Jorge, additional more...
- Published
- 2019
- Full Text
- View/download PDF
6. Adverse treatment outcomes in multidrug resistant tuberculosis are beyond the microbe drug interaction: results of a multiple correspondence analysis.
- Author
-
Tobón, Ángela, Rueda, Johana, Cáceres, Diego H., Mejía, Gloria I., Zapata, Elsa M., Montes, Fernando, Ospina, Antonio, Fadul, Santiago, Paniagua, Lizeth, and Robledo, Jaime
- Subjects
TREATMENT effectiveness ,DRUG interactions ,OBSTRUCTIVE lung diseases ,MULTIDRUG-resistant tuberculosis ,DIRECTLY observed therapy ,TUBERCULOSIS - Abstract
Copyright of Biomédica: Revista del Instituto Nacional de Salud is the property of Instituto Nacional de Salud of Colombia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) more...
- Published
- 2020
7. GenoType MTBDR plus 1.0 ® para la detección de resistencia cruzada entre isoniacida y etionamida en aislamientos de Mycobacterium tuberculosis multirresistentes
- Author
-
Rueda, Johana, Realpe, Teresa, Mejía, Gloria, Zapata, Elsa, and Robledo, Jaime
- Subjects
isoniazid ,análisis de secuencia ,sequence analysis ,tuberculosis, multidrug-resistant ,ethionamide ,isoniacida ,Mycobacterium tuberculosis ,mutation ,tuberculosis resistente a múltiples medicamentos ,mutación ,etionamida - Abstract
Introducción. Una parte de los aislamientos de Mycobacterium tuberculosis multirresistente también presenta resistencia a la etionamida. Es importante determinar si la resistencia a la isoniacida es independiente o se cruza con la resistencia a la etionamida, ya que si sucede lo segundo habría que reevaluar el tratamiento antituberculoso de segunda línea. La prueba molecular GenoType MTBDR plus ® detecta las mutaciones asociadas con la resistencia a isoniacida y podría detectar la resistencia cruzada a la etionamida. Objetivo. Evaluar la prueba GenoType MTBDR plus ® y comparar su desempeño con el de la secuenciación, en la detección de mutaciones en el gen katG y en el promotor inhA en aislamientos clínicos de M. tuberculosis multirresistente. Materiales y métodos. Se utilizaron el estuche comercial GenoType MTBDR plus 1.0 ® y la secuenciación para evaluar mutaciones en el gen katG y en el promotor inhA en 30 aislamientos de M. tuberculosis multirresistente con resistencia a la etionamida. La cepa de laboratorio H37Rv y tres aislamientos sensibles a los medicamentos de primera línea, sirvieron de control. Resultados. Al comparar los resultados de la secuenciación y de la prueba GenoType MTBDR plus ® , el índice kappa fue de 1. Todos los aislamientos resistentes a la isoniacida y la etionamida tenían las mutaciones detectadas con la prueba GenoTypeMTBDR plus ® en el gen katG, y 40 % de ellos, las detectadas en el promotor inhA. Mediante secuenciación se encontraron, además, mutaciones en katG en posiciones diferentes a las detectadas por la prueba GenoType MTBDR plus ® . Conclusión. La prueba GenoTypeMTBDR plus ® tiene la capacidad de detectar rápidamente la resistencia a isoniacida. Además, los resultados del estudio sugieren que también podría utilizarse como prueba de tamización para detectar la resistencia cruzada a etionamida. Introduction: A variable proportion of isolates of multidrug-resistant Mycobacterium tuberculosis also presents resistance to ethionamide. It is important to determine whether resistance to isoniazid is independent or crossed with resistance to ethionamide, given that this could lead to the re-evaluation of second-line anti-tuberculosis treatment. The GenoType MTBDR plus ® molecular test is used for the detection of MDR-MTB, as it identifies mutations associated with resistance to isoniazide and could detect cross-resistance with ethionamide. Objective: To evaluate the performance of GenoType MTBDR plus ® in comparison with sequencing in the detection of mutations in gene katG and promotor inhA in clinical isolates of multidrug-resistant M. tuberculosis . Materials and methods: The GenoType MTBDR plus 1.0 ® commercial kit and sequencing were used to evaluate mutations in gene katG and promotor inhA in 30 multidrug-resistant M. tuberculosis isolates that were resistant to ethionamide. The laboratory strain H37Rv and three pan-sensitive isolates acted as controls. Results: The kappa index for the comparison between the results of sequencing and GenoType MTBDR plus ® was 1. All the isolates resistant to isoniazid and ethionamide had the mutations detected by GenoTypeMTBDR plus ® in the katG gene and 40% of them in promotor inhA. Sequencing also revealed katG mutations in positions different to those detected by GenoType MTBDR plus ® . Conclusion: GenoType MTBDR plus ® is able to detect resistance to isoniazid rapidly. Our results suggest that it could also be used to screen for cross-resistance with ethionamide. more...
- Published
- 2015
8. La práctica docente en el contexto del diseño, aplicación y retroalimentación colaborativa de una estrategia que promueva el desarrollo de habilidades de pensamiento creativo
- Author
-
Marenco Tejeda, David, Peña Leyva, Fátima de la, Meriño Berdugo, Arlyb Esther, Navarro Rueda, Johana, and Borjas, Mónica Patricia
- Subjects
Pensamiento creativo--Enseñanza ,Pedagogía ,Ciencias del ambiente--Enseñanza - Abstract
Tesis (Magíster en Educación) -- Universidad del Norte. Programa de Maestría en Educación, 2008. Esta investigación pretendió analizar la práctica docente a través del diseño, aplicación y retroalimentación colaborativa de una estrategia pedagógica que promoviera el desarrollo de habilidades de pensamiento creativo, en 8°, enmarcando el estudio dentro del paradigma cualitativo, bajo el diseño de investigación-acción colaborativa, el cual se desarrolló en tres etapas: en la primera se reconoció la realidad educativa para sensibilizar al profesorado de la problemática; en la segunda se diseñó en la acción la estrategia y en la última se reflexionó y retroalimentó la estrategia. Para sistematizar la información recolectada se acordaron tres metacategorías: saber específico, saber hacer y saber convivir juntos, las cuales permitieron concluir que: Es posible desarrollar habilidades de pensamiento creativo en todas las personas, niveles y áreas. Cualificarse e investigar permanentemente favorece el quehacer docente y por ende la calidad de la educación. El trabajo colaborativo permitió compartir experiencias para retroalimentar la praxis. more...
- Published
- 2012
9. GenoType MTBDRplus 1.0® for the detection of cross-resistance between isoniazide and ethionamide in isolates of multidrug-resistant Mycobacterium tuberculosis
- Author
-
Rueda, Johana, Realpe, Teresa, Mejía, Gloria, Zapata, Elsa, Robledo, Jaime, Rueda, Johana, Realpe, Teresa, Mejía, Gloria, Zapata, Elsa, and Robledo, Jaime
- Abstract
Introduction: A variable proportion of isolates of multidrug-resistant Mycobacterium tuberculosis also presents resistance to ethionamide. It is important to determine whether resistance to isoniazid is independent or crossed with resistance to ethionamide, given that this could lead to the re-evaluation of second-line anti-tuberculosis treatment. The GenoType MTBDRplus® molecular test is used for the detection of MDR-MTB, as it identifies mutations associated with resistance to isoniazide and could detect cross-resistance with ethionamide.Objective: To evaluate the performance of GenoType MTBDRplus® in comparison with sequencing in the detection of mutations in gene katG and promotor inhA in clinical isolates of multidrug-resistant M. tuberculosis.Materials and methods: The GenoType MTBDRplus 1.0® commercial kit and sequencing were used to evaluate mutations in gene katG and promotor inhA in 30 multidrug-resistant M. tuberculosis isolates that were resistant to ethionamide. The laboratory strain H37Rv and three pan-sensitive isolates acted as controls.Results: The kappa index for the comparison between the results of sequencing and GenoType MTBDRplus® was 1. All the isolates resistant to isoniazid and ethionamide had the mutations detected by GenoTypeMTBDRplus® in the katG gene and 40% of them in promotor inhA. Sequencing also revealed katG mutations in positions different to those detected by GenoType MTBDRplus®.Conclusion: GenoType MTBDRplus® is able to detect resistance to isoniazid rapidly. Our results suggest that it could also be used to screen for cross-resistance with ethionamide., Introducción. Una parte de los aislamientos de Mycobacterium tuberculosis multirresistente también presenta resistencia a la etionamida. Es importante determinar si la resistencia a la isoniacida es independiente o se cruza con la resistencia a la etionamida, ya que si sucede lo segundo habría que reevaluar el tratamiento antituberculoso de segunda línea. La prueba molecular GenoType MTBDRplus® detecta las mutaciones asociadas con la resistencia a isoniacida y podría detectar la resistencia cruzada a la etionamida.Objetivo. Evaluar la prueba GenoType MTBDRplus® y comparar su desempeño con el de la secuenciación, en la detección de mutaciones en el gen katG y en el promotor inhA en aislamientos clínicos de M. tuberculosis multirresistente.Materiales y métodos. Se utilizaron el estuche comercial GenoType MTBDRplus 1.0® y la secuenciación para evaluar mutaciones en el gen katG y en el promotor inhA en 30 aislamientos de M. tuberculosis multirresistente con resistencia a la etionamida. La cepa de laboratorio H37Rv y tres aislamientos sensibles a los medicamentos de primera línea, sirvieron de control.Resultados. Al comparar los resultados de la secuenciación y de la prueba GenoType MTBDRplus®, el índice kappa fue de 1. Todos los aislamientos resistentes a la isoniacida y la etionamida tenían las mutaciones detectadas con la prueba GenoTypeMTBDRplus® en el gen katG, y 40 % de ellos, las detectadas en el promotor inhA. Mediante secuenciación se encontraron, además, mutaciones en katG en posiciones diferentes a las detectadas por la prueba GenoType MTBDRplus®.Conclusión. La prueba GenoTypeMTBDRplus® tiene la capacidad de detectar rápidamente la resistencia a isoniacida. Además, los resultados del estudio sugieren que también podría utilizarse como prueba de tamización para detectar la resistencia cruzada a etionamida. more...
- Published
- 2015
10. Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates
- Author
-
Rueda, Johana, primary, Realpe, Teresa, additional, Mejia, Gloria Isabel, additional, Zapata, Elsa, additional, Rozo, Juan Carlos, additional, Ferro, Beatriz Eugenia, additional, and Robledo, Jaime, additional more...
- Published
- 2015
- Full Text
- View/download PDF
11. GenoType® MTBDRplus 1.0 para detección de resistencia cruzada entre isoniazida y etionamida en aislamientos de Mycobacterium tuberculosis multifármaco-resistente
- Author
-
Rueda, Johana, primary, Realpe, Teresa, additional, Mejía, Gloria, additional, Zapata, Elsa, additional, and Robledo, Jaime, additional
- Published
- 2015
- Full Text
- View/download PDF
12. Poppers' Maculopathy.
- Author
-
Cañote Flores, Renzo and Rueda Rueda, Johana
- Subjects
- *
OPTICAL coherence tomography , *VISUAL acuity - Abstract
We report a case of visual alterations after the first use of poppers in a young male patient. A 32-year-old male patient with no past medical history presented with decreased central visual acuity and phosphenes in both eyes. He admitted the use of poppers a day before the symptoms began. Optical coherence tomography showed bilateral disruption of the ellipsoid zone. Poppers' use is increasing in young people and so is the possibility of visual and structural alterations that can persist over time as a result of macular toxicity. [ABSTRACT FROM AUTHOR] more...
- Published
- 2019
- Full Text
- View/download PDF
13. Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosisClinical Isolates
- Author
-
Rueda, Johana, Realpe, Teresa, Mejia, Gloria Isabel, Zapata, Elsa, Rozo, Juan Carlos, Ferro, Beatriz Eugenia, and Robledo, Jaime
- Abstract
ABSTRACTEthionamide (ETH) is an antibiotic used for the treatment of multidrug-resistant (MDR) tuberculosis (TB) (MDR-TB), and its use may be limited with the emergence of resistance in the Mycobacterium tuberculosispopulation. ETH resistance in M. tuberculosisis phenomenon independent or cross related when accompanied with isoniazid (INH) resistance. In most cases, resistance to INH and ETH is explained by mutations in the inhApromoter and in the following genes: katG, ethA, ethR, mshA, ndh, and inhA. We sequenced the above genes in 64 M. tuberculosisisolates (n= 57 ETH-resistant MDR-TB isolates; n= 3 ETH-susceptible MDR-TB isolates; and n= 4 fully susceptible isolates). Each isolate was tested for susceptibility to first- and second-line drugs using the agar proportion method. Mutations were observed in ETH-resistant MDR-TB isolates at the following rates: 100% in katG, 72% in ethA, 45.6% in mshA, 8.7% in ndh, and 33.3% in inhAor its promoter. Of the three ETH-susceptible MDR-TB isolates, all showed mutations in katG; one had a mutation in ethA, and another, in mshAand inhA. Finally, of the four fully susceptible isolates, two showed no detectable mutation in the studied genes, and two had mutations in mshAgene unrelated to the resistance. Mutations not previously reported were found in the ethA, mshA, katG, and ndhgenes. The concordance between the phenotypic susceptibility testing to INH and ETH and the sequencing was 1 and 0.45, respectively. Among isolates exhibiting INH resistance, the high frequency of independent resistance and cross-resistance with ETH in the M. tuberculosisisolates suggests the need to confirm the susceptibility to ETH before considering it in the treatment of patients with MDR-TB. more...
- Published
- 2015
- Full Text
- View/download PDF
14. [GenoType MTBDR plus 1.0® for the detection of cross-resistance between isoniazide and ethionamide in isolates of multidrug-resistant Mycobacterium tuberculosis].
- Author
-
Rueda J, Realpe T, Mejía G, Zapata E, and Robledo J
- Subjects
- Antitubercular Agents metabolism, DNA, Bacterial genetics, Ethionamide metabolism, Genotype, Humans, Isoniazid metabolism, Mycobacterium tuberculosis enzymology, Mycobacterium tuberculosis genetics, Mycobacterium tuberculosis isolation & purification, Polymerase Chain Reaction methods, Promoter Regions, Genetic genetics, Antitubercular Agents pharmacology, Bacterial Proteins genetics, Bacterial Typing Techniques methods, Catalase genetics, Drug Resistance, Multiple, Bacterial genetics, Ethionamide pharmacology, Genotyping Techniques, Isoniazid pharmacology, Mycobacterium tuberculosis drug effects, Oxidoreductases genetics, Sequence Analysis, DNA methods, Tuberculosis, Multidrug-Resistant microbiology
- Abstract
Introduction: A variable proportion of isolates of multidrug-resistant Mycobacterium tuberculosis also presents resistance to ethionamide. It is important to determine whether resistance to isoniazid is independent or crossed with resistance to ethionamide, given that this could lead to the re-evaluation of second-line anti-tuberculosis treatment. The GenoType MTBDR plus ® molecular test is used for the detection of MDR-MTB, as it identifies mutations associated with resistance to isoniazide and could detect cross-resistance with ethionamide., Objective: To evaluate the performance of GenoType MTBDR plus ® in comparison with sequencing in the detection of mutations in gene katG and promotor inhA in clinical isolates of multidrug-resistant M. tuberculosis ., Materials and Methods: The GenoType MTBDR plus 1.0® commercial kit and sequencing were used to evaluate mutations in gene katG and promotor inhA in 30 multidrug-resistant M. tuberculosis isolates that were resistant to ethionamide. The laboratory strain H37Rv and three pan-sensitive isolates acted as controls., Results: The kappa index for the comparison between the results of sequencing and GenoType MTBDR plus® was 1. All the isolates resistant to isoniazid and ethionamide had the mutations detected by GenoTypeMTBDR plus® in the katG gene and 40% of them in promotor inhA. Sequencing also revealed katG mutations in positions different to those detected by GenoType MTBDR plus®., Conclusion: GenoType MTBDR plus ® is able to detect resistance to isoniazid rapidly. Our results suggest that it could also be used to screen for cross-resistance with ethionamide. more...
- Published
- 2015
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.